Search By Type of Job
- Medical Sales Representative (161)
- Sales Management (32)
- Market Access (31)
- Business Development (28)
- Medical/Clinical (23)
- Marketing (12)
- Medical Education (7)
- Medical Communications (6)
- Senior Management (5)
- Clinical Research (5)
- Medical Research (3)
- Pre-clinical R&D (2)
- Medical Writing (2)
- Market Research (1)
- SmartPeople: Difficult breathing
- Dr Raja Flores is chief of Thoracic Surgery at The Mount Sinai Medical Center in New York, where he also directs the Thoracic Surgical Oncology Program. As a leading expert in the study and treatment of malignant pleural mesothelioma, Dr Flores wrote a frequently-cited study titled “Extrapleural Pneumonectomy versus Pleurectomy Decortication in the management of malignant pleural mesothelioma” which reviewed the effectiveness of two of the most common surgical treatments for pleural mesothelioma over a sixteen-year period.In addition to his research, Dr Flores has taken an innovative approach ...
- Network Connection
- Seamus O’Neil, chief executive of the Academic Health Science Network for the North East and North Cumbria, on bridging the gap between pharma and the NHS What is your background and current role?I am currently the chief executive of the Academic Health Science Network for the North East and North Cumbria (NENC). My background is in NHS research management and before that I was a clinical scientist within the NHS (in genetics). What does your day-to-day work involve?Managing people, budgets and programmes. However, it is more exciting than it sounds. The people are fabulous, the ...
- Birth Right
- The Zika outbreak has brought the issue of congenital anomalies to the forefront of the science community and the public’s mind. We ask Helen Dolk, Professor of Epidemiology at the University of Ulster, about the challenges of working in this areaWhat is your background and current role?I have been working for over 30 years on epidemiologic research relating to pregnancy, congenital anomalies or health effects of environmental exposures. For 15 years, until recently, I was project leader of EUROCAT – European Surveillance of Congenital Anomalies and director of the associated WHO ...
- Building blocks
- World-leading cancer researcher and entrepenuer Professor Tony Kouzarides offer some advice on connecting academia and pharma, setting up R&D companies and juggling several jobs at onceWhat is your background?I’ve always been interested in cancer, especially the human genes that cause it. My basic interest is molecular mechanisms of cancer, and that’s what my lab works on.Essentially I’ve been working on epigenetics for the last two decades. Twenty years ago my lab found one of the first enzymes that modify histone proteins – CBP – and had the first evidence that it was involved in cancer ...
- New to the market
- What does the industry have in store for aspiring marketers? We ask last year’s New Marketer of the Year, Thom RenwickWhat is your background and current role?I studied at King’s College London and Cranfield School of Management then took up a graduate role in the sales team at Roche. This was a great platform for pharmaceutical marketing as it gave me an understanding of the healthcare professional from an on-the-ground perspective, and insight into how to add value for them.I’m currently a brand manager at Roche, working on prelaunch brands in oncology. One of the great things about the ...
- Talking about a revolution
- We live in exciting times of cutting-edge science, truly innovative new medicines and positive changes towards patient-centricity, says Janssen’s Jane GriffithsWhat is your current role?As Company Group Chairman for Janssen EMEA I am responsible for the commercial group in the region. How do you start your day?I get up early, take my dog for a quick walk (trying to increase my steps) then check my diary to get my head around the day ahead. After that, I head for the office or Heathrow airport. What are the main issues in oncology at the moment?The main issue is that cancer still ...
- Mission possible
- For more than 20 years, John Crowley has made it his mission to discover ever-more effective medicines to treat devastating rare genetic disordersDeveloping medicines for rare diseases requires an entirely different mindset, says John Crowley, chairman and CEO of rare disease company Amicus Therapeutics. “Developing drugs in rare diseases is very different from more prevalent disorders – the clinical studies are very small, you have different endpoints and biomarkers, different regulatory paradigms and different types of sales and marketing, plus the focus on the patient is intense. It takes ...
- SmartPeople: Mr NICE Guy
- One day a month, MSD's Paul Robinson helps to make decisions that affect tens of thousands of patients. He sits on one of NICE's Technology Appraisal Committees, a group of 15-20 healthcare professionals, NHS managers and patient representatives who decide which drugs the NHS in England will pay for and which it won't"When I tell people that I sit on a NICE committee but also work for a pharma company, eyebrows sometimes shoot up," says Paul, executive director, scientific medical and patient perspective at Merck Sharp and Dohme. "But what I believe I bring to the table is my deep ...
- SmartPeople: Growth spurt
- After spending most of his career in the US, Takeda UK managing director Adam Zaeske arrived on our shores last year intent on transforming the company into an agile speciality businessWhat is your current role?I am managing director for the UK and Ireland business with responsibility to lead the commercial organisation – for me, that means bringing products to market that serve patients. I've been with Takeda for 12 years, in a number of roles, starting in product planning then leading teams in marketing, sales and market access, the three legs of the commercial stool. Prior to Takeda I was ...
- SmartPeople: Padraic Dempsey
- Uniphar’s Padraic Dempsey offers insights into his working day, opinions on the UK and Ireland industries and a sneak peek into his pastWhat is your current role and how did you get there?I joined Uniphar two years ago as managing director of manufacturer services, a €700 million business that first entered the UK market with the acquisition of Star, the market-leading outsourcing and resourcing company. By leveraging Star’s platform we have built a fully integrated manufacturing services business for the UK and Ireland that combines supply chain, outsourcing and resourcing, nurse services ...
PharmaTimes Media’s recruitment hub offers the widest range of career opportunities for the pharmaceutical and healthcare industries.
Candidates benefit from an effective and efficient service designed to offer all that they need to seek new career opportunities.
Contact Anna Yeardley to place your job advertisement
Anna Yeardley - Business Development Manager
Tel: +44 (0)20 7240 6999
PharmaTimes Media Limited
Telephone: +44 (0)7240 6999
Upload your CV quickly
Upload your CV to our secure server & send it to jobs whenever you wish. You can also make your details available to Employers & Recruiters (confidential or named) which means they can find you, as well as you finding them!
Working in Healthcare - News and advice
Pharma Job News
- Movers January/February
- The NHS Confederation has appointed Niall Dickson as its new chief executive. Niall has just completed seven years as chief executive of the General Medical Council (GMC) and before that was chief executive of The King's Fund. He was for many years the BBC's social affairs editor. During his time at the GMC from 2010 to 2016, Niall delivered a raft of reforms. These included an expansion of its responsibilities for medical education and training, the introduction of revalidation in 2012, the introduction of language checks for doctors from Europe in 2014, and the establishment of the ...
- Movers December
- Helen Gordon will leave the RPS next year to become the chief executive of The Royal Society of Medicine. Helen remains in post at RPS until February 2017 and will join the RSM in March. She joined the Royal Pharmaceutical Society in July 2010 and developed its role, work and impact as the newly dedicated professional body for pharmacists after the organisation split from its regulatory function that year. She has championed the introduction of a professional development and recognition system for pharmacists, the RPS Faculty and Foundation programmes, published professional standards as well ...
- October Movers
- GSK has appointed Emma Walmsley as its CEO designate. She will succeed Andrew Witty as GSK CEO when he retires on 31 March 2017. Emma is currently CEO of GSK Consumer Healthcare, established in 2015 following completion of GSK’s three-part transaction with Novartis. Prior to this, Emma was president of GSK Consumer Healthcare and has been a member of GSK’s Corporate Executive Team since 2011. Emma joined GSK in 2010 from L’Oreal where, over the course of her 17-year career, she held a variety of marketing and general management roles in the UK, Europe and USA. From 2007 she was based in ...